EblueprintOff-label uses of biologics in dermatology: Interferon and intravenous immunoglobulin (Part 1 of 2)
Section snippets
References (395)
- et al.
The interferon system: an overview
Eur J Paediatr Neurol
(2002) - et al.
Large keratoacanthomas treated with intralesional interferon alfa-2a
J Am Acad Dermatol
(1993) - et al.
Treatment of neoplastic skin lesions with intralesional interferon
J Am Acad Dermatol
(1989) - et al.
Efficacy of recombinant alpha-interferon 2a and 13-cis-retinoic acid in the treatment of squamous cell carcinoma
Ann Oncol
(1994) - et al.
Treatment of basal cell carcinoma with intralesional interferon
J Am Acad Dermatol
(1986) - et al.
Intralesional interferon therapy for basal cell carcinoma
J Am Acad Dermatol
(1990) - et al.
Treatment of aggressive basal cell carcinoma with intralesional interferon: evaluation of efficacy by Mohs surgery
J Am Acad Dermatol
(1992) Intralesional interferon alfa-2b in the treatment of basal cell carcinoma: immunohistochemical study on cellular immune reaction leading to tumor regression
J Am Acad Dermatol
(1991)- et al.
Intralesional alfa-2a interferon therapy for basal cell carcinoma
Cancer Lett
(1995) - et al.
Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms
J Am Acad Dermatol
(2004)
Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II
Blood
Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial
J Am Acad Dermatol
Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alpha: a 10-year experience at a single institution
J Am Acad Dermatol
Treatment of massive or life-threatening hemangiomas with recombinant alpha(2a)-interferon
Otolaryngol Head Neck Surg
Recombinant interferon alfa-2b in the treatment of vision-threatening capillary hemangiomas in childhood
J AAPOS
Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy
J Pediatr
Response of deep tufted angioma to interferon alfa
J Am Acad Dermatol
Interferon treatment of patients with chronic urticaria and mastocytosis
J Am Acad Dermatol
Systemic mastocytosis associated with chronic myelomonocytic leukemia: clinical features and response to interferon alfa therapy
J Am Acad Dermatol
Short-term keloid treatment in vivo with human interferon alfa-2b results in a selective and persistent normalization of keloidal fibroblast collagen, glycosaminoglycan, and collagenase production in vitro
J Am Acad Dermatol
Myofibroblasts and apoptosis in human hypertrophic scars: the effect of interferon-alpha2b
Surgery
Recurrence rates of excised keloids treated with postoperative triamcinolone acetonide injections or interferon alfa-2b injections
J Am Acad Dermatol
Carbon dioxide laser ablation associated with interferon alfa-2b injections reduces the recurrence of keloids
J Am Acad Dermatol
Successful treatment of disseminated verrucae vulgares with interferon-beta
J Am Acad Dermatol
Response of warts in epidermodysplasia verruciformis to treatment with systemic and intralesional alpha interferon
J Am Acad Dermatol
Treatment of epidermodysplasia verruciformis with a combination of acitretin and interferon alfa-2a
J Am Acad Dermatol
Cytokines: interleukin and interferon therapy in dermatology
Clin Exp Dermatol
Intralesional interferon alpha-2b in the treatment of basal cell carcinoma and squamous cell carcinoma: revisited
Dermatol Surg
Recombinant interferon-gamma (rIFN-gamma) in dermatology
J Invest Dermatol
Effect of intralesional alpha 2-interferon on actinic keratoses
Arch Dermatol
The effect of topical interferon alpha 2b on actinic keratoses
J Dermatol Surg Oncol
Treatment of cutaneous squamous cell carcinomas by intralesional interferon alfa-2b therapy
Arch Dermatol
13-cis-Retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin
J Natl Cancer Inst
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer
J Clin Oncol
Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study
Arch Surg
Use of recombinant interferon alfa-2b in the treatment of basal cell carcinoma
Dermatology
Intralesional recombinant interferon beta-1a in the treatment of basal cell carcinoma: results of an open-label multicentre study
Eur J Dermatol
The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas
Arch Dermatol
Treatment of basal cell carcinoma with intralesional interferon alpha-2b
J R Soc Med
Comparison of the effects of intralesional interferon alfa-2a, 2b and the combination of 2a and 2b in the treatment of basal cell carcinoma
J Dermatol
The role of interferon alpha 2b as an adjunctive treatment in the management of aggressive basal cell carcinoma of the eyelids
Acta Ophthalmol Scand
Consideration of the cost of interferon alfa-2b in the treatment of basal cell carcinoma
Australas J Dermatol
Recombinant interferon alfa-2b in plaque-phase mycosis fungoides: intralesional and low-dose intramuscular therapy
Arch Dermatol
The therapeutic role of interferons and monoclonal antibodies in cutaneous T-cell lymphomas
J Invest Dermatol
Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma
J Invest Dermatol
Biological modifiers (etretinate (changed from etetrinate) and alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma
Cancer Biother Radiopharm
The treatment of 45 patients with cutaneous T-cell lymphoma with low doses of interferon-alpha 2a and etretinate
Br J Dermatol
Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma
Cancer
Marche Regional Multicentric Study Group of Cutaneous Lymphomas. Long-term experience with low-dose interferon-alpha and PUVA in the management of early mycosis fungoides
Eur J Haematol
Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma
J Invest Dermatol
Cited by (21)
Interferons
2012, Comprehensive Dermatologic Drug Therapy: Expert Consult - Online and PrintImmunotherapies in Dermatologic Disorders
2012, Medical Clinics of North AmericaCitation Excerpt :A patient with IgA pemphigus showed improvement with alefacept and mycophenolate mofetil (1 g/d). Other studies used alefacept for erythema nodosum, lichen planus, and pyoderma gangrenosum.26,64 Alemtuzumab is a humanized anti-CD52 monoclonal antibody.
Management of Epidermolysis Bullosa Acquisita
2011, Dermatologic ClinicsCitation Excerpt :There have reports of azathioprine, cyclophosphamide, and gold, as additional adjuvants in small studies.12,14 IVIG is used as an off-label treatment for AIBD including EBA.24 It is generally given at doses of 2 g/kg over 3 to 5 days, and reports of its use in fewer than 20 patients have suggested success in treating recalcitrant EBA.
Treatment of scleromyxedema and the dermatoneuro syndrome with intravenous immunoglobulin
2009, Journal of the American Academy of DermatologyCitation Excerpt :The majority of adverse effects are mild and include headache, nausea, low-grade fever, arthralgias, anxiety, flushing, and urticaria.33,45 Other rare and more serious adverse effects of IVIG infusion include anaphylaxis, aseptic meningitis, acute renal failure, stroke, myocardial infarction, deep venous thrombosis, and pulmonary embolism.33,45 Pretreatment with acetaminophen, nonsteroidal anti-inflammatory drugs, and diphenhydramine is thought to be effective in preventing fever, headache, and urticaria, respectively.33
Present and future of biologic therapy in dermatology
2008, Actas Dermo-SifiliograficasModulating acute neuroinflammation in intracerebral hemorrhage: the potential promise of currently approved medications for multiple sclerosis
2019, Immunopharmacology and Immunotoxicology
Funding sources: None.
Conflicts of interest: None identified.